The impact of biological interventions for ulcerative colitis on health-related quality of life

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Leblanc, Katie ^a   Mosli, Mahmoud ^b,c   Baker, Kenneth A ^a   Macdonald, John K ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; NATALIZUMAB; RITUXIMAB; VEDOLIZUMAB;

ARTICLE; BIOLOGICAL THERAPY; DATA ANALYSIS; HUMAN; INFORMATION PROCESSING; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; SYSTEMATIC REVIEW; THERAPY EFFECT; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 85048485785     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008655.pub2     Document Type: Article

References (22)

1. Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflammatory Bowel Diseases 2005;11(10):909-18.
2. Bernklev T, Jahnsen J, Henriksen M, Lygren I, Aadland E, Sauar J, et al.Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2006;12(5):402-12.
3. Boonen A, Dagnelie PC, Feleus A, Hesselink MA, Muris JW, Stockbrügger RW, et al.The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study. Inflammatory Bowel Diseases 2002;8(6):382-9.
4. Feagan BG. Review article: economic issues in Crohn's disease--assessing the effects of new treatments on health-related quality of life. Alimentary Pharmacology and Therapeutics 1999;13(Suppl 4):29-37; discussion 38.
5. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, et al.The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. American Journal of Gastroenterology 2007;102(4):794-802.
6. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al.A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96(3):804-10.
7. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
8. Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand?. Current Gastroenterology Reports 2010;12(6):471-8.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
10. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
11. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al.Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106(2):287-96.
12. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory BowelDisease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. American Journal of Gastroenterology 1996;91(8):1571-8.
13. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflammatory Bowel Diseases 2008;14(4):554-65.
14. Janke KH, Raible A, Bauer M, Clemens P, Meisner C, Häuser W, et al.Questions on life satisfaction (FLZM) in inflammatory bowel disease. International Journal of Colorectal Disease 2004;19(4):343-53.
15. Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflammatory Bowel Diseases 2005;11(3):272-86.
16. Konig HH, Ulsofer A, Gregor M, von Tirpiz C, Reinshagen M, Adler G, Leidl R. Validation of the EuroQoL questionnaire in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology 2002;14(11):1205-15.
17. Marri SR, Buchman AL. The education and employment status of patients with inflammatory bowel diseases. Inflammatory Bowel Diseases 2005;11(2):171-7.
18. Petrak F, Hardt J, Clement T, Börner N, Egle UT, Hoffmann SO. Impaired health-related quality of life in inflammatory bowel diseases: psychosocial impact and coping styles in a national German sample. Scandinavian Journal of Gastroenterology 2001;36(4):375-82.
19. Reinisch W, Sandborn WJ, Bala M, Yan S, Feagan BG, Rutgeerts P, et al.Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflammatory Bowel Diseases 2007;13(9):1135-40.
20. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
21. Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clinical and Experimental Gastroenterology 2009;2:101-9.
22. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.